Bacterial methylomes and antibiotic potentiation

Cohen et al., Nature Genetics, 2016

Cohen et al., Nature Genetics, 2016

Antibiotics emerged as miracle drugs and “silver bullets” in the early 20th century, revolutionizing medicine and our ability to combat infectious disease while positively impacting health and lifespans on a large scale. This remarkable triumph held steady for many years, and consequently antibiotic research and development diminished as a priority due to the seeming defeat of bacterial infections. However, the selective pressure that came with antibiotic exposure led to the development of bacterial resistance to these compounds, motivating renewed interest in what is now an extremely important public health issue. Mechanisms of resistance are many and ever-evolving, and we know now that it is not a matter of IF bacteria will become resistant to a class of antibiotics, but when. The search for new and potentially exploitable bacterial vulnerabilities, then, becomes a constant enterprise in order for us to keep pace with the bacteria in the antibiotics/resistance arms race.

Cohen et al., Nature Genetics, 2016

Cohen et al., Nature Genetics, 2016

A new study this week in Nature Genetics describes how manipulating the bacterial DNA methylome affects susceptibility to multiple classes of antibiotics. The authors observed that deleting the dam gene, encoding a DNA methyltransferase, from E. coli causes increased susceptibility to sub-lethal doses of the β-lactam antibiotic ampicillin. Dam specifically methylates GATC sites, and deletion of any of the other three DNA methyltransferases found in E. coli had no effect on the level of antibiotic susceptibility. Using SMRT sequencing, the authors saw that genome-wide GATC methylation patterns did not change after exposure to ampicillin, so they sought alternative explanations for the observed phenotype. Continue reading

Group urges speedier approvals for badly needed antibiotics

Infectious-disease doctors have proposed a speedier, easier approval process for drug companies developing antibiotics against untreatable illnesses.

The Infectious Diseases Society of America (IDSA) made the proposal today at a hearing of a subcommittee of the US House of Representatives Committee on Energy and Commerce. The hearing focused on reauthorization of the Prescription Drug User Fee Act, which funds the US Food and Drug Administration (FDA).

According to IDSA, only two or three drug companies are still conducting research on antibiotics in the United States, even as antibiotic-resistant strains of bacteria are becoming an ever more urgent health problem. A bill proposed by Rep. Phil Gingrey (R-GA) called the Generating Antibiotic Incentives Now Act (GAIN), would grant incentives to companies that develop antibiotics against drug-resistant bacteria. IDSA is proposing that lawmakers also create a ‘Special Population Limited Medical Use’ (SPLMU) mechanism that would allow companies to conduct clinical trials in fewer patients and obtain more streamlined approvals for the drugs if they are intended to treat patients for which no other drugs are available.

The new mechanism would also reserve these drugs specifically for use in patients harboring pathogens resistant to all other treatments. That provision is designed to address a major concern among doctors and the FDA that new antibiotics will quickly lose their effectiveness if they are overused.

“We need antibiotics to be used for life-threatening infections that lack medical treatments … and not for your kid’s ear infection,” Janet Woodcock, head of the FDA’s drugs center, told reporters on Wednesday, according to Reuters.